- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04728893
Werkzaamheid en veiligheid van Nemtabrutinib (MK-1026) bij deelnemers met hematologische maligniteiten (MK-1026-003)
Een fase 2-onderzoek om de werkzaamheid en veiligheid van MK-1026 te evalueren bij deelnemers met hematologische maligniteiten
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This study will be performed in 2 parts: Dose Escalation and Confirmation (Part 1) and Cohort Expansion (Part 2). Following determination of the recommended phase 2 dose (RP2D) in Part 1, the study plans to proceed with Part 2 using 8 disease-specific expansion cohorts (Cohorts A to H).
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Toll Free Number
- Telefoonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studie Locaties
-
-
-
Caba, Argentinië, C1114AAN
- Werving
- FUNDALEU ( Site 0104)
-
Contact:
- Study Coordinator
- Telefoonnummer: 5411 48771046
-
Córdoba, Argentinië, X5016KEH
- Werving
- Hospital Privado Universitario de Córdoba ( Site 0107)
-
Contact:
- Study Coordinator
- Telefoonnummer: +541569634187
-
Mendoza, Argentinië, M5500AYB
- Voltooid
- Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentinië, C1118AAT
- Werving
- Hospital Aleman ( Site 0102)
-
Contact:
- Study Coordinator
- Telefoonnummer: +541148277000
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentinië, C1431FWO
- Werving
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
-
Contact:
- Study Coordinator
- Telefoonnummer: +541152990247
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentinië, S2000DEJ
- Werving
- Fundacion Estudios Clinicos ( Site 0112)
-
Contact:
- Study Coordinator
- Telefoonnummer: +54 0341 238 4171
-
-
-
-
New South Wales
-
Sydney, New South Wales, Australië, 2747
- Voltooid
- Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
-
-
Victoria
-
Box Hill, Victoria, Australië, 3128
- Werving
- Box Hill Hospital ( Site 0203)
-
Contact:
- Study Coordinator
- Telefoonnummer: +611300342255
-
-
Western Australia
-
Nedlands, Western Australia, Australië, 6009
- Werving
- Sir Charles Gairdner Hospital ( Site 0200)
-
Contact:
- Study Coordinator
- Telefoonnummer: +61864573333
-
-
-
-
-
Rio de Janeiro, Brazilië, 20231-050
- Werving
- Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
-
Contact:
- Study Coordinator
- Telefoonnummer: +552132076564
-
São Paulo, Brazilië, 01321-001
- Werving
- Hospital Paulistano - Amil Clinical Research ( Site 0311)
-
Contact:
- Study Coordinator
- Telefoonnummer: +551130161340
-
São Paulo, Brazilië, 01321-001
- Actief, niet wervend
- BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
-
-
São Paulo
-
São Paulo, São Paulo, Brazilië, 05403-000
- Werving
- Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
-
Contact:
- Study Coordinator
- Telefoonnummer: 551145737543
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Werving
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
-
Contact:
- Study Coordinator
- Telefoonnummer: 4035213723
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Werving
- The Ottawa Hospital ( Site 0404)
-
Contact:
- Study Coordinator
- Telefoonnummer: 613 737-7700
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
-
Contact:
- Study Coordinator
- Telefoonnummer: 416-946-2827
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Werving
- Jewish General Hospital ( Site 0400)
-
Contact:
- Study Coordinator
- Telefoonnummer: 5143408222 x 24572
-
Montreal, Quebec, Canada, H1T 2M4
- Werving
- CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
-
Contact:
- Study Coordinator
- Telefoonnummer: 5142523400
-
-
-
-
Anhui
-
Hefei, Anhui, China, 230071
- Actief, niet wervend
- Anhui Provincial Hospital ( Site 2808)
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100191
- Werving
- Peking University Third Hospital-Hematology ( Site 2827)
-
Contact:
- Study Coordinator
- Telefoonnummer: 010-82266699
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, China, 400072
- Actief, niet wervend
- The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Actief, niet wervend
- Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
-
-
Guangxi
-
Liuzhou, Guangxi, China, 545006
- Werving
- Liuzhou People's Hospital ( Site 2817)
-
Contact:
- Study Coordinator
- Telefoonnummer: +8607722662950
-
Nanning, Guangxi, China, 530028
- Werving
- Guangxi Medical University Cancer Hospital ( Site 2814)
-
Contact:
- Study Coordinator
- Telefoonnummer: +8607715323174
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Werving
- Henan Cancer Hospital-hematology department ( Site 2802)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0371-65588007
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Werving
- Wuhan Union Hospital ( Site 2816)
-
Contact:
- Study Coordinator
- Telefoonnummer: +8618627091655
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Werving
- The Second Xiangya Hospital of Central South University ( Site 2820)
-
Contact:
- Study Coordinator
- Telefoonnummer: +8613975806137
-
Changsha, Hunan, China, 410013
- Werving
- Hunan Cancer Hospital ( Site 2822)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0731-88651669
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Werving
- Jiangsu Province Hospital ( Site 2823)
-
Contact:
- Study Coordinator
- Telefoonnummer: 025-86211033
-
Xuzhou, Jiangsu, China, 221000
- Voltooid
- The Affiliated Hospital of Xuzhou Medical College ( Site 2818)
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Werving
- The First Affiliated Hospital of Nanchang University ( Site 2815)
-
Contact:
- Study Coordinator
- Telefoonnummer: 13970038386
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Werving
- The First Hospital of Jilin University-Hematology ( Site 2803)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0431-88786014
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Werving
- Fudan University Shanghai Cancer Center ( Site 2801)
-
Contact:
- Study Coordinator
- Telefoonnummer: +8602164175590
-
Shanghai, Shanghai Municipality, China, 200040
- Werving
- Huashan Hospital, Fudan University ( Site 2821)
-
Contact:
- Study Coordinator
- Telefoonnummer: 021-52889999
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Werving
- West China Hospital Sichuan University ( Site 2810)
-
Contact:
- Study Coordinator
- Telefoonnummer: +86028-85422114
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 301617
- Werving
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)
-
Contact:
- Study Coordinator
- Telefoonnummer: +8615900265415
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310002
- Werving
- The First Affiliated Hospital, Zhejiang University ( Site 2826)
-
Contact:
- Study Coordinator
- Telefoonnummer: 057187236114
-
-
-
-
Central Jutland
-
Aarhus N, Central Jutland, Denemarken, 8200
- Voltooid
- Aarhus University Hospital ( Site 0702)
-
-
North Denmark
-
Aalborg, North Denmark, Denemarken, 9000
- Werving
- Aalborg Universitetshospital ( Site 0703)
-
Contact:
- Study Coordinator
- Telefoonnummer: +45 97660000
-
-
Region Sjælland
-
Koege, Region Sjælland, Denemarken, 4600
- Werving
- Sjællands Universitetshospital Køge ( Site 0701)
-
Contact:
- Study Coordinator
- Telefoonnummer: +45 46323200
-
-
Region Syddanmark
-
Odense C, Region Syddanmark, Denemarken, 5000
- Voltooid
- Odense University Hospital ( Site 0705)
-
-
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Duitsland, 89081
- Werving
- Universitaetsklinikum Ulm. ( Site 0906)
-
Contact:
- Study Coordinator
- Telefoonnummer: + 49 731 500 45901
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Duitsland, 50937
- Werving
- Universitaetsklinikum Koeln ( Site 0901)
-
Contact:
- Study Coordinator
- Telefoonnummer: +4922147897046
-
Siegen, North Rhine-Westphalia, Duitsland, 57072
- Voltooid
- St. Marien-Krankenhaus Siegen ( Site 0914)
-
-
Saxony
-
Dresden, Saxony, Duitsland, 01307
- Werving
- Universitaetsklinikum Carl Gustav Carus ( Site 0902)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0049 351 458 5692
-
-
-
-
-
Paris, Frankrijk, 75010
- Werving
- Hopital Saint Louis ( Site 0805)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33142499236
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankrijk, 06202
- Werving
- Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33 4 92 03 57 85
-
-
Auvergne-Rhône-Alpes
-
Pierre-Bénite, Auvergne-Rhône-Alpes, Frankrijk, 69495
- Werving
- Centre Hospitalier Lyon-Sud ( Site 0804)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33478864348
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, Frankrijk, 13009
- Werving
- Institut Paoli-Calmettes ( Site 0803)
-
Contact:
- Study Coordinator
- Telefoonnummer: +33491223537
-
-
Yvelines
-
Le Chesnay, Yvelines, Frankrijk, 78150
- Voltooid
- Centre Hospitalier de Versailles ( Site 0809)
-
-
-
-
-
Budapest, Hongarije, 1122
- Werving
- Orszagos Onkologiai Intezet ( Site 1200)
-
Contact:
- Study Coordinator
- Telefoonnummer: +3612248600
-
-
Baranya
-
Pécs, Baranya, Hongarije, 7624
- Werving
- Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)
-
Contact:
- Study Coordinator
- Telefoonnummer: +3672536000
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Hongarije, 4032
- Werving
- Debreceni Egyetem Klinikai Kozpont ( Site 1201)
-
Contact:
- Study Coordinator
- Telefoonnummer: +3652255196
-
-
Szabolcs-Szatmár-Bereg
-
Nyíregyháza, Szabolcs-Szatmár-Bereg, Hongarije, 4400
- Werving
- Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)
-
Contact:
- Study Coordinator
- Telefoonnummer: +3642599700
-
-
-
-
-
Dublin, Ierland, Dublin 9
- Werving
- Beaumont Hospital ( Site 2900)
-
Contact:
- Study Coordinator
- Telefoonnummer: +35318092010
-
Limerick, Ierland, V94 F858
- Actief, niet wervend
- University Hospital Limerick ( Site 2903)
-
-
-
-
-
Afula, Israël, 1834111
- Werving
- Ha Emek Medical Center ( Site 1305)
-
Contact:
- Study Coordinator
- Telefoonnummer: 972-46494052
-
Beersheba, Israël, 8410101
- Werving
- Soroka Medical Center ( Site 1307)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97286403827
-
Haifa, Israël, 3109601
- Werving
- Rambam Medical Center ( Site 1301)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97247772547
-
Jerusalem, Israël, 9112001
- Werving
- Hadassah Ein Karem Jerusalem ( Site 1300)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97226778180
-
Ramat Gan, Israël, 5262001
- Werving
- Chaim Sheba Medical Center ( Site 1302)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97235308401
-
Rehovot, Israël, 76100
- Werving
- Kaplan Medical Center ( Site 1304)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97289441726
-
Tel Aviv, Israël, 6423906
- Werving
- Sourasky Medical Center ( Site 1303)
-
Contact:
- Study Coordinator
- Telefoonnummer: +97236973782
-
-
-
-
-
Bari, Italië, 70124
- Voltooid
- Istituto Tumori Giovanni Paolo II ( Site 1409)
-
Bologna, Italië, 40138
- Werving
- A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)
-
Contact:
- Study Coordinator
- Telefoonnummer: +390516363680
-
Brescia, Italië, 25123
- Werving
- ASST Spedali Civili di Brescia ( Site 1408)
-
Contact:
- Study Coordinator
- Telefoonnummer: +39 0303996416
-
Milan, Italië, 20132
- Werving
- IRCCS Ospedale San Raffaele ( Site 1402)
-
Contact:
- Study Coordinator
- Telefoonnummer: 00390226434797
-
Naples, Italië, 80131
- Werving
- Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)
-
Contact:
- Study Coordinator
- Telefoonnummer: +39 0815903 382
-
Pavia, Italië, 27100
- Werving
- Fondazione IRCCS Policlinico San Matteo ( Site 1407)
-
Contact:
- Study Coordinator
- Telefoonnummer: +39 0382503084
-
Reggio Emilia, Italië, 42123
- Werving
- IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)
-
Contact:
- Study Coordinator
- Telefoonnummer: +39 0522295654
-
Roma, Italië, 00161
- Voltooid
- Policlinico Umberto I ( Site 1404)
-
-
-
-
-
Kyiv, Oekraïne, 03022
- Werving
- National Cancer Institute ( Site 2507)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380672091427
-
-
Cherkasy Oblast
-
Cherkassy, Cherkasy Oblast, Oekraïne, 18009
- Actief, niet wervend
- MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Oekraïne, 76008
- Voltooid
- Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Oekraïne, 79044
- Werving
- Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)
-
Contact:
- Study Coordinator
- Telefoonnummer: +380322352276
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-727
- Werving
- Pratia MCM Krakow ( Site 1601)
-
Contact:
- Study Coordinator
- Telefoonnummer: 48 12 2954135
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polen, 50-367
- Voltooid
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 02-781
- Werving
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)
-
Contact:
- Study Coordinator
- Telefoonnummer: +48225462223
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, Polen, 45-061
- Voltooid
- Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)
-
-
Pomeranian Voivodeship
-
Gdynia, Pomeranian Voivodeship, Polen, 81-519
- Voltooid
- Szpitale Pomorskie Sp. z o.o. ( Site 1600)
-
-
-
-
-
Brasov, Roemenië, 500052
- Werving
- Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0729075567
-
Iași, Roemenië, 700483
- Werving
- Institutul Regional de Oncologie Iasi ( Site 1801)
-
Contact:
- Study Coordinator
- Telefoonnummer: 40374278811
-
-
Bucharest
-
Bucharest, Bucharest, Roemenië, 030171
- Werving
- Spitalul Clinic Colțea ( Site 1805)
-
Contact:
- Study Coordinator
- Telefoonnummer: 0040213874100
-
-
Constanța County
-
Ovidiu, Constanța County, Roemenië, 905900
- Voltooid
- Ovidius Clinical Hospital ( Site 1804)
-
-
-
-
-
Alicante, Spanje, 03010
- Werving
- Hospital General Universitario de Alicante ( Site 2007)
-
Contact:
- Study Coordinator
- Telefoonnummer: 965 93 30 00
-
Barcelona, Spanje, 08035
- Werving
- Hospital Universitari Vall d'Hebron ( Site 2001)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34934893806
-
Madrid, Spanje, 28041
- Werving
- Hospital Universitario 12 de Octubre ( Site 2003)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34917792809
-
Madrid, Spanje, 28222
- Werving
- Hospital Puerta de Hierro ( Site 2009)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34911916000
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Spanje, 08908
- Werving
- Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)
-
Contact:
- Study Coordinator
- Telefoonnummer: +34932607750
-
-
Castille and León
-
Salamanca, Castille and León, Spanje, 37007
- Werving
- Hospital Universitario de Salamanca ( Site 2002)
-
Contact:
- Study Coordinator
- Telefoonnummer: 34923 29 11 00x55974
-
-
La Coruna
-
A Coruña, La Coruna, Spanje, 15006
- Werving
- CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)
-
Contact:
- Study Coordinator
- Telefoonnummer: 34981178000
-
-
-
-
-
Hradec Králové, Tsjechië, 500 05
- Werving
- Fakultni nemocnice Hradec Kralove ( Site 0601)
-
Contact:
- Study Coordinator
- Telefoonnummer: +420495832159
-
-
Brno-mesto
-
Brno, Brno-mesto, Tsjechië, 625 00
- Werving
- Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)
-
Contact:
- Study Coordinator
- Telefoonnummer: +420532233642
-
-
-
-
-
Ankara, Turkije (Türkiye), 06590
- Werving
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)
-
Contact:
- Study Coordinator
- Telefoonnummer: +903125957099
-
Istanbul, Turkije (Türkiye), 34365
- Voltooid
- VKV Amerikan Hastanesi ( Site 2403)
-
Istanbul, Turkije (Türkiye), 34381
- Werving
- Sisli Florence Nightingale Hastanesi ( Site 2407)
-
Contact:
- Study Coordinator
- Telefoonnummer: +90 542 502 50 75
-
Izmir, Turkije (Türkiye), 35340
- Actief, niet wervend
- Dokuz Eylül Üniversitesi-Hematology ( Site 2402)
-
-
Istanbul
-
Stanbul, Istanbul, Turkije (Türkiye), 34214
- Actief, niet wervend
- Mega Medipol-Hematology ( Site 2406)
-
-
-
-
-
Manchester, Verenigd Koninkrijk, M20 4BX
- Werving
- The Christie NHS Foundation Trust ( Site 2602)
-
Contact:
- Study Coordinator
- Telefoonnummer: 01619561217
-
-
Bristol, City of
-
Bristol, Bristol, City of, Verenigd Koninkrijk, BS2 8ED
- Werving
- Bristol Haematology and Oncology Centre ( Site 2610)
-
Contact:
- Study Coordinator
- Telefoonnummer: 01173426733
-
-
England
-
Nottingham, England, Verenigd Koninkrijk, NG5 1PF
- Werving
- Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)
-
Contact:
- Study Coordinator
- Telefoonnummer: +441159691169
-
Windsor, England, Verenigd Koninkrijk, SL4 3HD
- Werving
- GenesisCare - Windsor ( Site 2608)
-
Contact:
- Study Coordinator
- Telefoonnummer: +447989474250
-
-
London, City of
-
London, London, City of, Verenigd Koninkrijk, W1G 6AD
- Werving
- Sarah Cannon Research Institute UK ( Site 2612)
-
Contact:
- Study Coordinator
- Telefoonnummer: 02032195234
-
-
Oxfordshire
-
Oxford, Oxfordshire, Verenigd Koninkrijk, OX4 6LB
- Werving
- GenesisCare - Oxford ( Site 2607)
-
Contact:
- Study Coordinator
- Telefoonnummer: +447989474250
-
-
Suffolk
-
Newmarket, Suffolk, Verenigd Koninkrijk, CB8 7XN
- Werving
- GenesisCare - Cambridge ( Site 2611)
-
Contact:
- Study Coordinator
- Telefoonnummer: 01223 655145
-
-
Surrey
-
Sutton, Surrey, Verenigd Koninkrijk, SM2 5PT
- Werving
- The Royal Marsden NHS Foundation Trust. ( Site 2606)
-
Contact:
- Study Coordinator
- Telefoonnummer: 020 8642 6011
-
-
-
-
Arkansas
-
Springdale, Arkansas, Verenigde Staten, 72762
- Werving
- Highlands Oncology Group ( Site 2728)
-
Contact:
- Study Coordinator
- Telefoonnummer: 479-872-8130
-
-
California
-
La Jolla, California, Verenigde Staten, 92093-0698
- Werving
- University of California San Diego Moores Cancer Center ( Site 2717)
-
Contact:
- Study Coordinator
- Telefoonnummer: 858-534-5201
-
Torrance, California, Verenigde Staten, 90502
- Voltooid
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- Werving
- Colorado Blood Cancer Institute ( Site 2726)
-
Contact:
- Study Coordinator
- Telefoonnummer: 720-754-4800
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- Voltooid
- The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Actief, niet wervend
- Mayo Clinic - Rochester ( Site 2706)
-
-
New Jersey
-
East Brunswick, New Jersey, Verenigde Staten, 08816
- Werving
- Astera Cancer Care ( Site 2732)
-
Contact:
- Study Coordinator
- Telefoonnummer: 732-672-6405
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Werving
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
-
Contact:
- Study Coordinator
- Telefoonnummer: 551-996-3003
-
-
North Dakota
-
Fargo, North Dakota, Verenigde Staten, 58102
- Voltooid
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- Werving
- UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
-
Contact:
- Study Coordinator
- Telefoonnummer: 972-695-9450
-
-
Washington
-
Spokane, Washington, Verenigde Staten, 99208
- Werving
- Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
-
Contact:
- Study Coordinator
- Telefoonnummer: 509-462-2273
-
-
-
-
-
Seoul, Zuid -Korea, 03722
- Werving
- Severance Hospital Yonsei University Health System ( Site 2201)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82222281972
-
Seoul, Zuid -Korea, 06351
- Werving
- Samsung Medical Center ( Site 2200)
-
Contact:
- Study Coordinator
- Telefoonnummer: +82234106548
-
-
-
-
Canton Ticino
-
Bellinzona, Canton Ticino, Zwitserland, 6500
- Werving
- Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)
-
Contact:
- Study Coordinator
- Telefoonnummer: +41918118540
-
-
Canton of Bern
-
Bern, Canton of Bern, Zwitserland, 3010
- Werving
- Inselspital Bern ( Site 2303)
-
Contact:
- Study Coordinator
- Telefoonnummer: +41316329023
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
- Has a life expectancy of at least 3 months, based on the investigator assessment
- Has the ability to swallow and retain oral medication
- Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
- Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
- Has adequate organ function
- Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
- Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention
- Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is >350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART
Part 1 and Part 2 (Cohorts A to C and J)
-
Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with
- At least 2 lines of prior therapy (Part 1 only)
- Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines
- Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive
- Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy
- Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J
- Has active disease for CLL/SLL clearly documented to initiate therapy
- For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1)
Part 2 (Cohorts D to G)
- Has a confirmed diagnosis of and meets the following prior therapy requirements:
- Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D)
- Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E)
- Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen
- Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G)
- Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan
- Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening
Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi
- Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease
- Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%
- Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival
Exclusion Criteria:
- Has active HBV/HCV infection (Part 1 and Part 2)
- Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded
- Has active central nervous system (CNS) disease
- Has an active infection requiring systemic therapy
- Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
- Has any clinically significant gastrointestinal abnormalities that might alter absorption
- History of severe bleeding disorders
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Nemtabrutinib
Participants receive nemtabrutinib orally once daily (QD) until progressive disease (PD) or discontinuation. |
Nemtabrutinib tablets administered orally QD.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)
Tijdsspanne: Up to ~56 days (Cycles 1-2, cycle = 28 days)
|
DLTs will be defined as toxicities observed during the first 2 cycles (8 weeks) of Part 1 and include: Grade ≥3 nonhematologic toxicity (except Grade 3 nausea, vomiting, diarrhea, rash, fatigue, and uncontrolled hypertension which will not be considered a DLT unless lasting ≥72 hours despite optimal supportive care); Grade 4 hematologic toxicity lasting >7 days (except Grade 3 lymphocytosis, Grade 4 platelet count decreased of any duration, or Grade 3 platelet count decreased if associated with bleeding); any Grade 3 or Grade 4 nonhematologic laboratory abnormality if values result in drug-induced liver injury, or medical intervention is required, or the abnormality leads to hospitalization, or the abnormality persists for >1 week (with exceptions); missing >25% of nemtabrutinib doses as a result of drug-related adverse events (AEs) during the first 2 cycles (8 weeks); Grade 5 toxicity. |
Up to ~56 days (Cycles 1-2, cycle = 28 days)
|
|
Part 1: Number of participants experiencing adverse events (AEs)
Tijdsspanne: Up to ~71 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 1. |
Up to ~71 months
|
|
Part 1: Number of participants discontinuing study treatment due to AEs
Tijdsspanne: Up to ~42 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 1. |
Up to ~42 months
|
|
Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)
Tijdsspanne: Up to ~61 months
|
ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR), or partial response (PR). CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~61 months
|
|
Part 2: ORR per Lugano criteria 2014 as assessed by ICR
Tijdsspanne: Up to ~61 months
|
ORR per Lugano criteria 2014 is defined as the percentage of participants achieving a CR or PR. CR defined as EITHER CR by imaging (computed tomography [CT]): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR complete metabolic response (CMR): score of 1, 2 or 3 on the 5-point scale assessing fluorodeoxyglucose (FDG) metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver) AND bone marrow (BM) normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the sum of the product of diameters [SPD] of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR Partial Metabolic Response (PMR) with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities. |
Up to ~61 months
|
|
Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICR
Tijdsspanne: Up to ~71 months
|
ORR per IWWM criteria 2014 is defined as the percentage of participants achieving a CR, very good partial response (VGPR), or PR. CR is defined as all lymph nodes are normal in size (none ≥15 mm), liver and spleen normal in size, serum immunoglobulin M (IgM) values in the normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with a second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in the abnormal portion of the spleen (if previously abnormal). |
Up to ~71 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1: Area Under the Curve (AUC) of Nemtabrutinib
Tijdsspanne: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 1: Minimum Concentration (Cmin) of Nemtabrutinib
Tijdsspanne: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 1: Maximum Concentration (Cmax) of Nemtabrutinib
Tijdsspanne: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 1 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1 and 2: Pre-dose, 2, 4, 6, 8, and 24 hours post-dose; Day 1 of Cycle 3: pre-dose and 2, 4, and 6 hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 1: ORR per iwCLL criteria 2018 as assessed by ICR
Tijdsspanne: Up to ~71 months
|
ORR per iwCLL 2018 criteria is defined as the percentage of participants achieving a CR, CRi, nPR, or PR. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~71 months
|
|
Part 1: Duration of Response (DOR) per iwCLL criteria 2018 as assessed by ICR
Tijdsspanne: Up to ~71 months
|
For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~71 months
|
|
Part 2: Number of participants experiencing AEs
Tijdsspanne: Up to ~61 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants experiencing AEs will be reported for Part 2. |
Up to ~61 months
|
|
Part 2: Number of participants discontinuing study treatment due to AEs
Tijdsspanne: Up to ~42 months
|
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants discontinuing study treatment due to an AE will be reported for Part 2. |
Up to ~42 months
|
|
Part 2: AUC of Nemtabrutinib
Tijdsspanne: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib AUC (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 2: Cmin of Nemtabrutinib
Tijdsspanne: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmin (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 2: Cmax of Nemtabrutinib
Tijdsspanne: At designated time points (up to ~57 days)
|
Blood samples will be obtained at designated time points during Part 2 for the assessment of nemtabrutinib Cmax (Day 1 of Cycles 1, 2, and 3: Pre-dose, 2, 4, 6, hours post-dose [up to ~57 days]). Each cycle is 28 days. |
At designated time points (up to ~57 days)
|
|
Part 2: DOR per iwCLL criteria 2018 as assessed by ICR
Tijdsspanne: Up to ~61 months
|
For participants with CR, CRi, nPR, or PR per iwCLL 2018 criteria, DOR is defined as the time from the first documented evidence of objective response until disease progression or death due to any cause, whichever occurs first. CR is defined as meeting the following criteria: no lymph nodes >1.5 cm, spleen size <13 cm, liver normal; no constitutional symptoms, normal lymphocyte count, platelets ≥100 x 10^9/L; hemoglobin ≥11 g/dL; and normocellular marrow (no CLL cells or B lymphoid nodules). CRi is defined as meeting CR criteria but with hypocellular bone marrow. nPR is defined as having features of CR but with lymphoid nodules in the marrow. PR is defined as ≥50% decrease in ≥2 of the following: lymph nodes, liver and/or spleen size, lymphocytes PLUS ≥1 of the following met: platelets ≥100 x 10^9/L or ≥50% increase from screening, hemoglobin >11 g/dL or ≥50% increase from screening, CLL cells or B lymphoid nodules in marrow. |
Up to ~61 months
|
|
Part 2: DOR per Lugano criteria 2014 as assessed by ICR
Tijdsspanne: Up to ~61 months
|
For participants with CR or PR per Lugano criteria 2014, DOR is defined as the time from the first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as EITHER CR by imaging (CT): all lymph nodes normal (none ≥15 mm) and normal liver and spleen OR CMR: score of 1, 2 or 3 on the 5-point scale assessing FDG metabolic activity in lymphomatous lesions (ranging from 1=no uptake above background to 5=uptake markedly higher than liver and/or new lesions) AND BM normal by morphology. PR defined as EITHER PR by imaging (CT) with ≥50% decrease in the SPD of target lesions, no worsening of nontarget lesions, no new lesions and ≥50% spleen abnormal portion OR PMR with score of 4 or 5 on the FDG 5-point scale (with no new lesions) and decreased overall uptake AND residual BM abnormalities; OR CR by imaging with residual BM abnormalities; OR PR by imaging without residual BM abnormalities. |
Up to ~61 months
|
|
Part 2: DOR per IWWM criteria 2014 as assessed by ICR
Tijdsspanne: Up to ~61 months
|
For participants with CR, VGPR, or PR per IWWM criteria 2014, DOR defined as the time from first documented evidence of objective response until PD or death due to any cause, whichever occurs first. CR defined as all lymph nodes normal in size (none ≥15 mm), liver and spleen normal in size, serum IgM values in normal range, disappearance of monoclonal protein by immunofixation (confirmation needed with second immunofixation at any subsequent timepoint), and no histological evidence of BM involvement. VGPR defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal), and ≥90% decrease from baseline in serum IgM, or serum IgM values in normal range. PR is defined as ≥50% decrease from baseline in SPD of lymph nodes (if abnormal at baseline), ≥50% decrease from baseline in serum IgM, and ≥50% decrease from baseline in abnormal portion of the spleen (if previously abnormal). |
Up to ~61 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Medical Director, Merck Sharp & Dohme LLC
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Vaatziekten
- Hart-en vaatziekten
- Neoplasmata per site
- Neoplasmata
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfatische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Lymfoom
- Neoplasmata, plasmacel
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Hemorragische aandoeningen
- Leukemie, Lymfoïde
- Leukemie
- Hemische en lymfatische ziekten
- Hematologische neoplasmata
- Lymfoom, non-Hodgkin
- Waldenström Macroglobulinemie
- Leukemie, B-cel
- ARQ531
Andere studie-ID-nummers
- 1026-003
- MK-1026-003 (Andere identificatie: MSD)
- 2020-002324-36 (EudraCT-nummer)
- U1111-1290-4004 (Register-ID: UTN)
- 2023-504931-42-00 (Register-ID: EU CT)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .